Headlines

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

read more

Join the newsletter

Subscribe to get our latest content by email.

    We respect your privacy. Unsubscribe at any time.

    Leave a Reply

    Your email address will not be published. Required fields are marked *